MON-LB008 PD-L1 Expression in Normal Endocrine Tissues

Introduction: Immune checkpoint inhibitor (ICI) therapy, including cytotoxic T-lymphocyte-associated protein 4 (CLTA-4) and programmed cell death 1 (PD-1) inhibitors, is revolutionizing cancer treatment. However, these agents are associated with immune-related adverse events (irAEs), most commonly e...

Descripción completa

Detalles Bibliográficos
Autores principales: Pollack, Rena, Kagan, Maayan, Dresner-Pollak, Rivka, Tzahi, Neuman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Endocrine Disruption
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550633/
http://dx.doi.org/10.1210/js.2019-MON-LB008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550633/
http://dx.doi.org/10.1210/js.2019-MON-LB008

Ejemplares similares